Lipid-Based Formulation of Baricitinib for the Topical Treatment of Psoriasis

Overview

Journal Pharmaceutics

Publisher MDPI

Date 2024 Oct 26

PMID 39458616

Authors

Roya Mohammadi-Meyabadi

Mireia Mallandrich

Negar Beirampour

Nuria Garros

Lupe Carolina Espinoza

Lilian Sosa

Joaquim Suner-Carbo

Maria Jose Rodriguez-Lagunas

Maria Luisa Garduno-Ramirez

Ana C Calpena-Campmany

Affiliations

Soon will be listed here.

Abstract

Background: Baricitinib, commonly used for autoimmune diseases, is typically administered orally, which can lead to systemic adverse effects. A topical formulation could potentially offer localized therapeutic effects while minimizing these side effects.

Objectives: This study focuses on developing a lipid-based topical formulation of baricitinib (BCT-OS) for treating psoriasis.

Methods: The optimized formulation was then assessed for physical, chemical, and biopharmaceutical characterization. Furthermore, the anti-inflammatory efficacy of the formulation was tested in a model of psoriasis induced by imiquimod in mice, and its tolerance was determined by the evaluation of biomechanical skin properties and an inflammation test model induced by xylol in mice.

Results: BCT-OS presented appropriate characteristics for skin administration in terms of pH, rheology, extensibility, and stability. The formulation also demonstrated a notable reduction in skin inflammation in the mouse model, and high tolerability without affecting the skin integrity.

Conclusions: BCT-OS shows promise as an alternative treatment for psoriasis, offering localized therapeutic benefits with a potentially improved safety profile compared to systemic administration.

References

Hagen M, Baker M . Skin penetration and tissue permeation after topical administration of diclofenac. Curr Med Res Opin. 2017; 33(9):1623-1634. DOI: 10.1080/03007995.2017.1352497. View

Abrego G, Alvarado H, Souto E, Guevara B, Halbaut Bellowa L, Parra A . Biopharmaceutical profile of pranoprofen-loaded PLGA nanoparticles containing hydrogels for ocular administration. Eur J Pharm Biopharm. 2015; 95(Pt B):261-70. DOI: 10.1016/j.ejpb.2015.01.026. View

Hiraganahalli Bhaskarmurthy D, Prince S . Effect of Baricitinib on TPA-induced psoriasis like skin inflammation. Life Sci. 2021; 279:119655. DOI: 10.1016/j.lfs.2021.119655. View

Silva-Abreu M, Sosa L, Espinoza L, Fabrega M, Rodriguez-Lagunas M, Mallandrich M . Efficacy of Apremilast Gels in Mouse Model of Imiquimod-Induced Psoriasis Skin Inflammation. Pharmaceutics. 2023; 15(10). PMC: 10610068. DOI: 10.3390/pharmaceutics15102403. View

Schmieder G, Draelos Z, Pariser D, Banfield C, Cox L, Hodge M . Efficacy and safety of the Janus kinase 1 inhibitor PF-04965842 in patients with moderate-to-severe psoriasis: phase II, randomized, double-blind, placebo-controlled study. Br J Dermatol. 2017; 179(1):54-62. DOI: 10.1111/bjd.16004. View

Papp K, Menter M, Raman M, Disch D, Schlichting D, Gaich C . A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasis. Br J Dermatol. 2016; 174(6):1266-76. DOI: 10.1111/bjd.14403. View

Griffiths C, Armstrong A, Gudjonsson J, Barker J . Psoriasis. Lancet. 2021; 397(10281):1301-1315. DOI: 10.1016/S0140-6736(20)32549-6. View

Ahmadi N, Rincon M, Silva-Abreu M, Sosa L, Pesantez-Narvaez J, Calpena A . Semi-Solid Dosage Forms Containing Pranoprofen-Loaded NLC as Topical Therapy for Local Inflammation: In Vitro, Ex Vivo and In Vivo Evaluation. Gels. 2023; 9(6). PMC: 10298032. DOI: 10.3390/gels9060448. View

Neelissen J, Bergenstahl B . In vitro permeation profile of a local anaesthetic compound from topical formulations with different rheological behaviour--verified by in vivo efficacy data. Eur J Pharm Sci. 2001; 14(3):229-36. DOI: 10.1016/s0928-0987(01)00181-6. View

10.

Sullivan Jr D, Gad S, Julien M . A review of the nonclinical safety of Transcutol®, a highly purified form of diethylene glycol monoethyl ether (DEGEE) used as a pharmaceutical excipient. Food Chem Toxicol. 2014; 72:40-50. DOI: 10.1016/j.fct.2014.06.028. View

11.

OShea J, Schwartz D, Villarino A, Gadina M, McInnes I, Laurence A . The JAK-STAT pathway: impact on human disease and therapeutic intervention. Annu Rev Med. 2015; 66:311-28. PMC: 5634336. DOI: 10.1146/annurev-med-051113-024537. View

12.

Fernandez-Campos F, Naveros B, Lopez Serrano O, Alonso Merino C, Campmany A . Evaluation of novel nystatin nanoemulsion for skin candidosis infections. Mycoses. 2012; 56(1):70-81. DOI: 10.1111/j.1439-0507.2012.02202.x. View

13.

Cui M, Wiraja C, Chew S, Xu C . Nanodelivery Systems for Topical Management of Skin Disorders. Mol Pharm. 2020; 18(2):491-505. DOI: 10.1021/acs.molpharmaceut.0c00154. View

14.

Kathe K, Kathpalia H . Film forming systems for topical and transdermal drug delivery. Asian J Pharm Sci. 2020; 12(6):487-497. PMC: 7032117. DOI: 10.1016/j.ajps.2017.07.004. View

15.

Kimball A, Jacobson C, Weiss S, Vreeland M, Wu Y . The psychosocial burden of psoriasis. Am J Clin Dermatol. 2005; 6(6):383-92. DOI: 10.2165/00128071-200506060-00005. View

16.

Sluczanowska-Glabowska S, Ziegler-Krawczyk A, Szumilas K, Pawlik A . Role of Janus Kinase Inhibitors in Therapy of Psoriasis. J Clin Med. 2021; 10(19). PMC: 8509829. DOI: 10.3390/jcm10194307. View

17.

Marwah H, Garg T, Goyal A, Rath G . Permeation enhancer strategies in transdermal drug delivery. Drug Deliv. 2014; 23(2):564-78. DOI: 10.3109/10717544.2014.935532. View

18.

Sosa L, Calpena A, Silva-Abreu M, Espinoza L, Rincon M, Bozal N . Thermoreversible Gel-Loaded Amphotericin B for the Treatment of Dermal and Vaginal Candidiasis. Pharmaceutics. 2019; 11(7). PMC: 6680481. DOI: 10.3390/pharmaceutics11070312. View

19.

Papp K, Menter A, Strober B, Langley R, Buonanno M, Wolk R . Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study. Br J Dermatol. 2012; 167(3):668-77. DOI: 10.1111/j.1365-2133.2012.11168.x. View

20.

Loden M . Effect of moisturizers on epidermal barrier function. Clin Dermatol. 2012; 30(3):286-96. DOI: 10.1016/j.clindermatol.2011.08.015. View